The present invention relates to an inhalation formulation of a drug in dry powder form for inhalation administration suitable for the treatment of airway obstructive diseases such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the present invention relates to a pharmaceutical composition for inhalation, the composition being a first powder, budesonide or a pharmaceutically acceptable salt thereof in an amount of more than 5% by weight of said first powder. A first powder and a second powder comprising: leucine in an amount of 5 to 70% by weight of the first powder； and lactose in an amount of 20 to 90% by weight of the first powder. Of formoterol or a pharmaceutically acceptable salt thereof in an amount of more than 1% by weight of the second powder, leucine in an amount of 5 to 70% by weight of the second powder, and A second powder comprising a lactose in an amount of 20-90% by weight, a mixture of a first lactose having an X50 of 35-75 μm and a second lactose having an X50 of 1.5-10 μm. 3 and the first and second lactose in the mixture A third powder having a source content of 85% to 96% and 4% to 15%, respectively. The composition has a fine particle fraction (FPF) greater than 60% and a delivery fraction (DF) greater than 80%.本発明は、喘息及び慢性閉塞性肺疾患（ＣＯＰＤ）などの気道の閉塞性疾患の治療に好適な、吸入投与用の乾燥粉末形態の薬物の吸入配合物に関する。特に、本発明は、吸入用の医薬組成物に関し、本組成物は、第１の粉末であって、前記第１の粉末の５重量％を超える量のブデソニドまたはその医薬的に許容される塩と、前記第１の粉末の５～７０重量％の量のロイシンと、前記第１の粉末の２０～９０重量％の量のラクトースとを含む、第１の粉末と、第２の粉末であって、前記第２の粉末の１重量％を超える量のホルモテロールまたはその医薬的に許容される塩と、前記第２の粉末の５～７０重量％の量のロイシンと、前記第２の粉末の２０～９０重量％の量のラクトースとを含む、第２の粉末と、３５～７５μｍのＸ５０を有する第１のラクトースと１．５～１０μｍのＸ５０を有する第２のラクトースとの混合物を含む第３の粉末であって、前記混合物中の前記第１及び第２のラクトースの含有量がそれぞれ８５％～９６％及び４％～１５％である、第３の粉末とを含む。前記組成物は、６０％を超える微粒子画分（ＦＰＦ）及び８０％を超える送達画分（ＤＦ）を有する。
